An Osaka University-led research team has recently published findings that provide a ray of hope for the millions of Parkinson’s disease (PD) sufferers worldwide. Although more common in those aged over sixty, PD can strike at any age, with an estimated prevalence of 41 per 100,000 people in their forties. And while not fatal in and of itself, the progressive neurodegeneration that is characteristic of PD can often cause secondary effects that lead to death.
The exact cause of PD is still a mystery, but researchers believe that both genetics and the environment are likely to play a part. Importantly though, all PD patients show a loss of dopaminergic neurons in the brain and increased levels of a protein called ?-synuclein, which accumulates in Lewy bodies. Lewy bodies are a pathological feature of both familial and sporadic forms of the disease, as well as some types of dementia.
In the study published this month in Scientific Reports, the team led by researchers from Osaka University’s Graduate School of Medicine focused on ?-synuclein as a target for a novel PD treatment.
“Although there are drugs that treat the symptoms associated with PD, there is no fundamental treatment to control the onset and progression of the disease,” explains lead author Takuya Uehara. “Therefore, we looked at ways to prevent the expression of ?-synuclein and effectively eliminate the physiological cause of PD.”
To do this, the researchers designed short fragments of DNA that are mirror images of sections of the ?-synuclein gene product. The constructs were stabilized by the addition of amido-bridging. The resulting fragments, called amido-bridged nucleic acid-modified antisense oligonucleotides (ASOs), bind to their matching mRNA sequence, preventing it from being translated into protein. After screening 50 different ASOs, the researchers settled on a 15-nucleotide sequence that decreased ?-synuclein mRNA levels by 81%.
“When we tested the ASO in a mouse model of PD, we found that it was delivered to the brain without the need for chemical carriers,” says co-lead author Chi-Jing Choong. “Further testing showed that the ASO effectively decreased ?-synuclein production in the mice and significantly reduced the severity of disease symptoms within 27 days of administration.”
Explains senior author of the study Hideki Mochizuki, “Our results showed that gene therapy using ?-synuclein-targeting ASOs is a promising strategy for the control and prevention of PD. We expect that in the future, this method will be used to not only successfully treat PD, but also dementia caused by ?-synuclein accumulation.”
Learn more: Stopping Parkinson’s disease before it starts
The Latest on: Parkinson’s disease
via Google News
The Latest on: Parkinson’s disease
- Study finds a one-time treatment eliminates Parkinson’s disease in miceon June 24, 2020 at 8:37 am
Researchers say their findings may represent a new approach to explore for the treatment of neurodegenerative conditions.
- Bar-Ilan named co-winners of Parkinson's disease research challengeon June 24, 2020 at 8:24 am
Ilan team, named “HaProzdor”, consisted of Ayala Matzner, Yuval El-Hanany and Prof. Izhar Bar-Gad from the Neural Interfaces Lab.
- Reversing a model of Parkinson’s disease with in situ converted nigral neuronson June 24, 2020 at 8:15 am
Depletion of the RNA-binding protein PTB (also known as PTBP1) in astrocytes reprograms these cells to become functional neurons and, in a mouse model of Parkinson’s disease, reverses the disease ...
- One-time treatment generates new neurons, eliminates Parkinson's disease in miceon June 24, 2020 at 8:04 am
UC San Diego researchers have discovered that a single treatment to inhibit a gene called PTB in mice converts native astrocytes, brain support cells, into neurons that produce the neurotransmitter ...
- A preliminary new method could restore the brain cells Parkinson’s disease patients loston June 24, 2020 at 8:02 am
The method, which has only been tested in mice, completely eliminated motor deficits by transforming one type of brain cell into another.
- Parkinson’s Disease Eliminated in Mice by One-Time Genetic Treatment that Generates New Neuronson June 24, 2020 at 8:02 am
Inhibiting a single gene converts many cell types directly into dopamine-producing neurons. Xiang-Dong Fu, PhD, has never been more excited about something in his entire career. He has long studied ...
- Scientists Reverse Parkinson’s Disease In Mice By Inhibiting A Single Geneon June 24, 2020 at 8:00 am
A team of researchers from the University of California, San Diego, have achieved a landmark victory in the fight against dementia by developing a one-off ...
- One-and-done gene therapy wipes out Parkinson's symptoms in mouse modelson June 24, 2020 at 8:00 am
A UCSD team developed a gene therapy technique that cripples the ability of the PTB gene to produce a functioning protein. In mouse models of Parkinson’s, the gene therapy turned supportive cells ...
- Parkinson's Disease Treatment Market : Dynamics, Segments, Size and Demand Analysis during 2020-2026on June 23, 2020 at 11:46 pm
Kenneth Research has published a detailed report on Parkinson's Disease Treatment Market which has been categorized ...
- Does Medical Marijuana Have a Role in Parkinson's Disease Care?on June 8, 2020 at 12:03 pm
Does Medical Marijuana Have a Role in Parkinson's Disease Care? By Serena McNiff HealthDay Reporter MONDAY, June 8, 2020 (HealthDay News) -- At a conference hosted two years ago by the Parkinson's ...
via Bing News